Bioventus Inc. (BVS)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1665988 · fiscal year ends in Dec
Closing price $13.32 on 30 Oct 2026; 52-week range $6.53 to $15.26.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $581.8M
- Revenue growth
- 3.1%
- Gross margin
- 68.7%
- Free cash flow
- $94.3M
- Market value
- $1.1B
- Cash
- $29.5M
- Debt
- $248.5M
- Debt to equity
- 1.09
- Shares outstanding
- 84.1M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $568.1M | $54.0M | $22.7M | $0.33 | $72.1M | 10-K filed 5 Mar 2026 |
| FY2024 | 31 Dec 2024 | $573.3M | -$15.2M | -$36.1M | -$0.56 | $37.8M | 10-K filed 11 Mar 2025 |
| FY2023 | 31 Dec 2023 | $512.3M | -$81.7M | -$156.2M | -$2.49 | $8.0M | 10-K filed 12 Mar 2024 |
| FY2022 | 31 Dec 2022 | $512.1M | -$167.2M | -$158.7M | -$2.59 | -$15.0M | 10-K filed 31 Mar 2023 |
| FY2021 | 31 Dec 2021 | $430.9M | $12.1M | $19.4M | -$0.15 | $9.5M | 10-K filed 11 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 27 Jun 2026 | $153.2M | $33.4M | $0.47 |
| Q1 FY2026 | 28 Mar 2026 | $132.1M | $3.1M | $0.04 |
| Q4 FY2025 | 31 Dec 2025 | $157.9M | – | – |
| Q3 FY2025 | 27 Sep 2025 | $138.7M | $3.2M | $0.05 |
| Q2 FY2025 | 28 Jun 2025 | $147.7M | $7.5M | $0.11 |
| Q1 FY2025 | 29 Mar 2025 | $123.9M | -$2.6M | -$0.04 |
| Q4 FY2024 | 31 Dec 2024 | $153.6M | -$156.0K | $0.00 |
| Q3 FY2024 | 28 Sep 2024 | $139.0M | -$5.2M | -$0.08 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2025
| Segment | Revenue | Share |
|---|---|---|
| U.S. | $502.1M | 88.4% |
| International | $66.0M | 11.6% |
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $502.1M | 88.4% |
| International | $66.0M | 11.6% |
Company events
The newest 8-K filings of 72 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 5 Aug 2026 | 8-K | Results, Other events | 2.02, 8.01, 9.01 |
| 4 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 21 May 2026 | 8-K | Investor update | 7.01 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 5 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 17 Nov 2025 | 8-K | Leadership change | 5.02 |
| 4 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 6 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 4 Aug 2025 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
| 31 Jul 2025 | 8-K | Other events | 8.01, 9.01 |
| 4 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 6 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 171 held.
| Filed | Form | Period |
|---|---|---|
| 5 Aug 2026 | 10-Q | 27 Jun 2026 |
| 5 Aug 2026 | 8-K | 5 Aug 2026 |
| 4 Jun 2026 | 8-K | 3 Jun 2026 |
| 29 May 2026 | SD | – |
| 21 May 2026 | 8-K | 21 May 2026 |
| 6 May 2026 | 10-Q | 28 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 22 Apr 2026 | ARS | 31 Dec 2025 |
| 22 Apr 2026 | DEFA14A | – |
| 22 Apr 2026 | DEF 14A | 31 Dec 2025 |
| 5 Mar 2026 | S-8 | – |
| 5 Mar 2026 | 10-K | 31 Dec 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 11 Mar 2026 | Mcmurry-Heath Michelle, Director | Sale outside a trading plan | 12,000 | $8.79 | $105.4K | 44,997 | 13 Mar 2026 |
| 4 Dec 2025 | Nohra Guy P, Director | Sale outside a trading plan | 10,000 | $7.57 | $75.7K | 116,610 | 8 Dec 2025 |
| 7 Nov 2025 | Mcmurry-Heath Michelle, Director | Sale outside a trading plan | 17,701 | $7.42 | $131.3K | 56,997 | 10 Nov 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 11 Mar 2026 | McMurry-Heath Michelle, Director | 12,000 | $105.7K | 11 Mar 2026 |
| 4 Dec 2025 | NOHRA GUY P, Director | 10,000 | $75.7K | 4 Dec 2025 |
| 7 Nov 2025 | McMurry-Heath Michelle, Director | 27,000 | $200.0K | 7 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 4.9% | 3.4M |
| 27 Jul 2026 | BlackRock, Inc. | 13G | 5.02% | 3.4M |
| 13 Feb 2026 | Nantahala Capital Management, LLC | 13G amended | 9.03% | 6.0M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 3.2M | +0.52% | 8.95 |
| 30 Sep 2026 | 3.2M | +7.87% | 6.7 |
| 15 Sep 2026 | 2.9M | +13.55% | 5.73 |
| 31 Aug 2026 | 2.6M | +10.56% | 4.65 |
| 14 Aug 2026 | 2.3M | -7.94% | 2.32 |
| 31 Jul 2026 | 2.5M | -7.09% | 3.88 |
| 15 Jul 2026 | 2.7M | +24.95% | 3.54 |
| 30 Jun 2026 | 2.2M | +13.19% | 3.25 |
Funds that hold it
From each fund's latest Form 13F.
179 funds held it at 30 Jun 2026: 97 added and 37 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Essex Woodlands Management, Inc. | 13,021,324 | $122.9M | 0 |
| Nantahala Capital Management, LLC | 12,000,558 | $113.3M | – |
| Juniper Investment Company, LLC | 6,939,357 | $65.5M | 0 |
| BlackRock, Inc. | 3,435,914 | $32.4M | +302,373 |
| Royce & Associates LP | 1,833,212 | $17.3M | +291,930 |
| Vanguard Capital Management LLC | 1,751,678 | $16.5M | +36,971 |
| Geode Capital Management, LLC | 1,365,716 | $12.9M | +197,469 |
| American Century Companies Inc. | 1,353,415 | $12.8M | +733,612 |
| Dimensional Fund Advisors LP | 1,128,465 | $10.7M | +255,327 |
| State Street Corp. | 1,104,878 | $10.4M | +116,511 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $26.3B, market value $110.9B
- 3M Co. (MMM): revenue $25.2B, market value $90.1B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $60.8B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $53.9B
- Medline Inc. (MDLN): revenue –, market value $42.2B
- Resmed Inc. (RMD): revenue $5.7B, market value $32.3B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $30.7B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $28.8B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.1B
- Solventum Corp. (SOLV): revenue $8.3B, market value $13.8B